Angie Davis

10/08/2026

Started BHRT and wondering why you don't feel better yet?

Hormone replacement therapy doesn't work like a pain reliever. You can't take a dose and expect years of hormonal changes to improve overnight. Your hormones influence everything from sleep and mood to brain function, metabolism, and energy. As hormone levels change with treatment, different tissues and systems may respond at different rates.

Some symptoms may improve within weeks, while others can take several months. And sometimes, adjustments to your treatment are necessary. So how long should you actually wait before expecting results, and when should your provider consider making changes?

Our latest blog explains what's happening inside your body during BHRT, why improvements happen on different timelines, and what you should realistically expect along the way.

Learn how long BHRT may take to improve symptoms, why results are gradual, and how follow-up testing and dose adjustments support better outcomes.

10/08/2026

GSM DOESN'T WAIT UNTIL MENOPAUSE, AND IT'S NOT JUST ABOUT VAGINAL DRYNESS!

Many women have never even heard of Genitourinary Syndrome of Menopause (GSM), yet they may already be experiencing symptoms during perimenopause without realizing their hormones could be contributing.

GSM develops as estrogen levels decline and fluctuate, affecting the tissues of the va**na, v***a, urethra, and bladder. Testosterone and other androgens also play a role in maintaining ge***al tissue health and sexual function.

And here's something important: You do NOT have to be fully menopausal to develop GSM. These changes can begin during perimenopause, even while you're still having regular menstrual cycles.

GSM can cause a surprisingly long list of symptoms, including:

- Vaginal dryness, even when you're not sexually active
- Vaginal burning, itching, or irritation
- Painful in*******se
- Decreased natural lubrication
- Tiny va**nal tears or fissures
- Spotting or bleeding after in*******se
- Vaginal tightness or narrowing
- Loss of va**nal elasticity
- Thinning and increased fragility of va**nal tissues
- Shrinking or thinning of the l***a
- Changes in cl****al tissue and its protective hood
- Decreased ge***al sensitivity
- Difficulty with sexual arousal or discomfort during intimacy
- Urinary urgency
- Frequent urination
- Waking during the night to urinate
- Burning or discomfort when urinating
- Recurrent urinary tract infections
- Urinary leakage or worsening bladder symptoms
- Discomfort when sitting, exercising, or wearing tight clothing

Not every woman experiences all these symptoms, and several can have other causes that need evaluation.

Estrogen does much more than regulate menstrual cycles or control hot flashes. Estrogen receptors are found throughout the va**nal, v***ar, urethral, and bladder tissues. When estrogen levels decline, these tissues can become thinner, drier, less elastic, and more vulnerable to irritation.

Systemic bioidentical hormone replacement therapy (BHRT), using estradiol can help restore estrogen signaling throughout the body. This can improve va**nal lubrication, tissue health, elasticity, and discomfort while also addressing other menopause-related symptoms such as hot flashes and night sweats.

And what about testosterone?

Androgen receptors are also present in ge***al tissues. Testosterone contributes to sexual desire, arousal, and aspects of sexual function. Declining androgen activity can contribute to changes women experience during the menopause transition.

THE BIGGEST THING WOMEN NEED TO UNDERSTAND?

GSM is not simply an inconvenience or an unavoidable part of getting older. Without effective treatment, symptoms can persist or worsen over time, affecting urinary health, sexual comfort, intimacy, and overall quality of life. And just because you're still having periods doesn't mean declining or fluctuating hormones aren't affecting these tissues.

Women deserve to understand these changes, recognize the symptoms early, and know that effective treatment options exist. You shouldn't have to wait until menopause to have your symptoms taken seriously.

10/07/2026

What if your worsening “menopause symptoms” aren’t just menopause?

Fatigue, brain fog, weight changes, hair thinning, mood shifts, sleep problems, and temperature changes can overlap heavily with thyroid dysfunction. During perimenopause and menopause, shifting estrogen and progesterone levels may also change how thyroid hormones are produced, converted, transported, and used by the body.

That overlap is one reason some women continue to feel terrible even after being told their thyroid labs are “normal.” This blog explains the connection between menopause and thyroid health, why symptoms can suddenly intensify in midlife, and why looking at the bigger hormonal picture can matter.

Learn why thyroid symptoms may feel worse during perimenopause and menopause, how hormone changes overlap, and when a deeper thyroid evaluation may help.

10/07/2026

A 2026 study looked at whether menopausal hormone therapy was linked to liver cancer risk in women. Researchers studied a very large group of women in Sweden and found that women using systemic menopausal hormone therapy had a lower risk of developing hepatocellular carcinoma, which is the most common type of primary liver cancer.

The association was especially noticeable in women age 60 and older. This study adds to the growing body of research showing that menopausal hormone therapy may affect much more than hot flashes alone. Hormones can influence many systems in the body, and research is continuing to expand our understanding of those effects.

10/06/2026

What if your blood sugar is making your menopause symptoms feel worse? A recent study looked at women with normal blood sugar compared with women who had prediabetes or type 2 diabetes. The women with blood sugar problems reported more menopause symptoms and said those symptoms were more severe.

In simple terms, the women with prediabetes or diabetes had about 28% more symptoms overall, and their total symptom severity was about 40% higher. The difference was especially noticeable in postmenopausal women.

Researchers do NOT yet know that high blood sugar directly causes worse menopause symptoms, but the study adds to growing evidence that hormone changes and metabolic health may be closely connected.

Estrogen changes can affect insulin sensitivity, body fat distribution, sleep, inflammation, and the way the body uses energy. At the same time, insulin resistance and poor blood sugar control may make some menopause symptoms harder on the body.

This is another reason menopause care may need to look at more than hormones alone. Blood sugar, insulin resistance, sleep, weight changes, cardiovascular health, and hormone levels can all be pieces of the same puzzle.

10/05/2026

What if the “standard” estrogen dose just isn’t enough after surgical menopause?
When the ovaries are removed, estrogen levels can fall abruptly rather than gradually, and some women continue struggling with hot flashes, sleep problems, brain fog, low energy, mood changes, and other symptoms even while using hormone therapy. This blog explains why women in surgical menopause may sometimes need a different approach to estradiol dosing and why treatment should be individualized instead of one-size-fits-all.

Learn why surgical menopause can cause sudden, severe hormone loss, why BHRT is important after o***y removal & why some women may need higher estrogen dosing.

10/05/2026

Hot flashes may be more than just an uncomfortable menopause symptom. They may be a warning sign that the brain and vascular system are struggling to adapt to the metabolic effects of estrogen loss.

As estrogen signaling declines, the brain can become less efficient at using glucose for energy. When that happens, it may begin shifting toward other fuel sources, including lipids stored within the brain.

Dr. Roberta Brinton’s research has described this transition from a brain that relies heavily on glucose toward one that begins using alternative fuel sources, including lipids from white matter, and yet, when women experience hot flashes, we often treat them like nothing more than an inconvenience.

We grab a fan.
We lower the thermostat.
We dress in layers.
We try to make the symptom more tolerable.

But what if the hot flash is actually telling us something important? Research has found that women experiencing more frequent physiologically measured hot flashes, particularly during sleep, can have a greater burden of white-matter hyperintensities in the brain.

White-matter hyperintensities are areas that appear brighter on certain MRI scans. They can reflect damage or changes in the brain’s small blood vessels and white matter, the tissue that helps different areas of the brain communicate with one another.

A greater burden of white-matter hyperintensities has been associated with an increased risk of stroke, problems with memory and thinking, cognitive decline, and dementia. They are also considered an important marker of cerebral small-vessel disease.

In one study of midlife women, more objectively measured hot flashes during sleep were associated with greater white-matter hyperintensity volume, even after researchers accounted for factors including blood pressure, cholesterol, insulin resistance, body weight, smoking, and sleep. Other research has also found that hot flashes can be accompanied by temporary reductions in blood flow to the brain. Frequent or persistent hot flashes have also been associated with poorer cardiovascular health, vascular dysfunction, and poorer cognitive outcomes.

Dr. Lisa Mosconi’s brain-imaging research has documented measurable changes during menopause involving brain glucose metabolism, brain structure, connectivity, and white matter.

If we are serious about protecting women’s bones, hearts, blood vessels, and brains as they age, then we also need to be willing to have a real conversation about estradiol. Simply making a hot flash more comfortable does not necessarily address what is happening underneath it.

Taking the batteries out of the smoke alarm does not put out the fire. Hot flashes deserve to be taken seriously. Treat them. Investigate them. And stop telling women they are something they simply have to live with.

10/02/2026

When cholesterol goes up after menopause, the first question should not always be, “How do we lower the LDL?” It should also be, “Why did it go up?”

Estrogen has an important effect on cholesterol, insulin sensitivity, blood vessels, and metabolism. As estrogen levels fall during menopause, LDL cholesterol often rises. That does not automatically mean every woman needs a cholesterol-lowering medication.

Statins can be very important for women who already have cardiovascular disease or who are at high risk. But for otherwise healthy women using them only for primary prevention, the overall benefit can depend heavily on the woman’s individual risk factors. Statins can also have side effects, including muscle symptoms, and they can modestly increase the risk of developing type 2 diabetes in some people.

This is where menopause deserves more attention. If the rise in cholesterol happened alongside the loss of estrogen, it makes sense to look at the entire picture instead of treating one lab value in isolation. Menopausal hormone therapy can improve some aspects of cholesterol and insulin sensitivity, although hormone therapy should not be prescribed solely to prevent heart disease.

The bigger point is that LDL is important, but it is only one part of cardiovascular risk. A woman’s blood pressure, blood sugar, triglycerides, HDL, smoking history, family history, inflammation, body composition, insulin resistance, and evidence of actual plaque or cardiovascular disease all matter too.

Instead of automatically assuming that every menopause-related increase in LDL needs medication, women deserve individualized cardiovascular risk assessment that also recognizes the major metabolic changes happening during menopause.

.com

09/14/2026

What if your hormone levels look “normal,” but you still don’t feel right?
SHBG can change how much estrogen and testosterone are actually available for your body to use, which can directly affect symptoms and treatment results. If hormone therapy isn’t working the way you expected, SHBG may be part of the reason.

Learn how SHBG affects free estrogen and testosterone, common causes of high or low SHBG, and why it may influence women’s hormone therapy results.

09/14/2026

“Nonhormonal” does not mean “risk-free.”

Veozah is often presented to women who want relief from hot flashes but are afraid of estrogen, particularly because they have been told hormone therapy may increase their risk of cancer. But women deserve the full picture when comparing their options.

Veozah, also known as fezolinetant, is a relatively new medication. It was FDA approved in 2023 for moderate to severe menopausal hot flashes. It works by blocking neurokinin 3 receptors involved in the brain’s temperature-regulation system. It can reduce hot flashes, but it does not replace estradiol or provide the other physiological effects that estrogen has throughout the body.

And being nonhormonal does not make it free of significant risks. Veozah now carries an FDA BOXED WARNING for hepatotoxicity because rare but serious liver injury has occurred after the medication reached the market. Women taking it require liver testing before treatment, monthly testing during the first three months, and additional testing at months 6 and 9.

There is another issue women should at least be aware of. During the clinical development of fezolinetant, FDA reviewers identified a numerical imbalance in malignancies between women receiving the medication and those receiving placebo, with the highest rate occurring in the 45 mg group, which is the dose ultimately approved.

This does NOT mean researchers have proven that Veozah causes cancer. The FDA concluded that the available evidence was not sufficient to establish a causal relationship and did not include a cancer warning in the prescribing information.

However, the discussion did not end there. More recent researchers have continued examining the neoplasm signal and the possible biological effects of blocking the NK3 receptor pathway. There are hypotheses involving kisspeptin signaling and other pathways associated with tumor growth, angiogenesis and metastasis. These are still areas of investigation, not proof that the medication causes cancer, but they are legitimate questions that require longer-term research.

And this is where perspective matters. We have decades of research on estrogen therapy and an enormous body of scientific literature examining its benefits, risks, dosing, routes of administration and long-term health effects. Estradiol has been studied in women for far longer than fezolinetant, a drug that has only been FDA approved since 2023.

That does not mean estradiol is appropriate for every woman, and it does not mean Veozah is a bad medication. Veozah may be an important option for women who cannot or do not want to use hormone therapy.

But women should not be told that one option is “dangerous because it is hormonal” while another is automatically “safer because it is nonhormonal.”

Every medication has benefits, risks and unanswered questions. Women deserve to know the known risks of estradiol. They also deserve to know the known risks and remaining uncertainties surrounding newer nonhormonal medications.

That is what informed consent should look like.